top of page

About Axia.Bio

Over more than 10 years, Axia.Bio is pioneering the field of Pharmacoeconomics in Brazil. Using our integrated knowledge of the intricate relationships between the market players, government and patient entities in the country, we are able to provide precise data and analysis.

Our established connections within the healthcare market allow us to have a full understanding of the Brazilian health systems complexities and their peculiarities. Axia.Bio consultants have more than 25 years experience in preparing studies and documentation for the Brazilian market while supporting our clients in achieving effective results.

Axia.Bio Commitments

  • Use all the experience of our professionals in conducting negotiations and presentations.

  •  Provide to the client more than just the technical outcome of a project.

  • Meet customer needs, while maintaining and ethical behavior and observing the good relationship practices with regulatory authorities.

  • Offer strategies for market approach and for presenting health technologies that meet our customers' need, and through robust evaluations reinforce the client’s positive reputation with the authorities and payers.

  • Develop projects with scientific rigor and methodology in order to meet customer needs.

  • Stay always updated, through participation in national and international events.

  • Follow ISPOR (International Society for Pharmacoeconomics and Outcomes Research) code of ethics.

  • Respect the local legislation and authorities.

  • Maintain confidentiality and discretion.

Results

  • More than 700 completed projects. 

 

  • Participation in peer-reviewed publications and in national and international conferences.

 

  • Award winning studies in national and international conferences.

 

  • Several cases of success in pricing and reimbursement of different technologies as reported by our customers.

 

  • Management of the UNIFESP Clinical Research Center. UNIFESP was voted the best university in the country and is the Quintiles preferential center for clinical trials in Brazil.

Conditions previously evaluated in Axia.Bio studies:
 

  • Food allergies

  • Rheumatoid Arthritis

  • Cervical Cancer

  • Breast Cancer

  • Lung Cancer

  • Renal cancer

  • Emergency Contraception 

  • Diabetes

  • Dyslipidemia

  • Crohn's Disease

  • Meningococcal disease

  • Bone metastatic disease

  • Chronic obstructive pulmonary disease

  • Acute postoperative pain

  • Schizophrenia

  • Fibromialgia

  • Hepatitis C

  • Urinary incontinence in women

  • Acute myocardial infarction

  • Serious infections in ICU

  • Acute lymphocytic leukemia

  • Chronic lymphocytic leukemia

  • Multiple Myeloma

  • Obesity

  • Osteoporosis

  • Community-acquired pneumonia

  • Psoriasis

  • Pulmonary thromboembolism

  • Deep vein thrombosis

  • Mechanical ventilation

  • Genital warts

  • Human immunodeficiency virus (HIV)

English

 Português

Global Service

Axia.Bio is a global company. We serve international customers reporting directly  to their headquarters or to their national representatives.

Working with a real consulting format, our company provides services to companies already established in the country as well as for those in the early stages of deployment.

bottom of page